It\u00b4s not just for the winter olympics: Team Switzerland reaches for biotech medals as well. The plasma specialist CSL is placing its bets on Swiss technology and has concluded a collaboration and option agreement with Memo Therapeutics. For products based on the Dropzylla platform, the agreement can reach a total value of up to CHF 265 million. The deal underlines the strategic importance of innovative antibody technologies from the Swiss biotech ecosystem.<\/p>\n
Specifically, Memo will develop recombinant polyclonal IgG candidates for which CSL has secured exclusive licensing options. If the option is exercised, Memo will receive research funding, a licence fee, as well as development and sales milestone payments for the first product, complemented by a single-digit royalty. In substance, the collaboration is aimed at new treatment options for rare and serious diseases.<\/p>\n
The Dropzylla platform is based on microfluidic single-cell technology for cloning human antibody repertoires. Recombinant polyclonal IgG antibodies are produced in the laboratory and mimic the natural immune response, offering potential advantages over plasma-derived products in terms of consistency, specificity and scalability.<\/p>\n
Positive for Memo<\/p>\n
For Memo, the deal represents an important milestone against the backdrop of mixed clinical news. In 2024, the company increased its Series C financing to CHF 45 million, thereby broadening its investor base in the European environment. At the same time, Memo suffered a setback last year: a Phase II trial with the anti-BK polyomavirus antibody potravitug missed its primary endpoint, but showed indications of histological improvements, meaning that further development into Phase III is planned. Whether and when a new trial will be set up is not yet communicated.<\/p>\n","protected":false},"excerpt":{"rendered":"It\u00b4s not just for the winter olympics: Team Switzerland reaches for biotech medals as well. The plasma specialist…\n","protected":false},"author":2,"featured_media":1274,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[1664,1665,1666,1667,1668,17,1669],"class_list":{"0":"post-1273","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-switzerland","8":"tag-antibody","9":"tag-australia","10":"tag-droplet","11":"tag-dropzylla","12":"tag-igg-polyclonal","13":"tag-switzerland","14":"tag-this-memo-sticks-csl-bites-in-switzerland-for-antibody-collaboration"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/1273","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=1273"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/1273\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/1274"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=1273"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=1273"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=1273"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}